Market Overview

UPDATE: Bank of America Downgrades Idenix Pharmaceuticals to Neutral on Regulatory Hurdles

Related IDIX
Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)
UPDATE: Deutsche Bank Initiates Coverage On Merck
Merck Aims at Superbugs with $9.5B Cubist Buy (Fox Business)

Bank of America lowered its rating on Idenix Pharmaceuticals (NASDAQ: IDIX) from Buy to Neutral and reduced its price objective from $8 to $6.

Bank of America commented, "We are downgrading IDIX shares from Buy to Neutral based on a series of recent conversations, with mgmt as well as industry & academic experts at recent conferences (ICAAC Sep 9-12, and EASL-AASLD HCV Special Conf Sep 14-16), that left us with limited hope that IDIX will convince the FDA to allow further clinical testing of HCV nuc drug candidates with a “G” base."

Idenix Pharmaceuticals closed at $5.64 on Tuesday.

Latest Ratings for IDIX

Jun 2014UBSDowngradesBuyNeutral
Jun 2014BairdUpgradesUnderperformNeutral
Jan 2014JMP SecuritiesDowngradesMarket PerformMarket Underperform

View More Analyst Ratings for IDIX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (IDIX)

Around the Web, We're Loving...

Get Benzinga's Newsletters